Kura Oncology, Inc. reports news on its precision oncology business, including commercialization of KOMZIFTI™ (ziftomenib), an FDA-approved once-daily oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. Company updates also cover small-molecule drug candidates designed to target cancer signaling pathways across hematologic malignancies and solid tumors.
Recurring KURA developments include financial results, corporate updates, clinical data presentations, collaboration-related milestones, healthcare conference participation and Nasdaq inducement grants. News on darlifarnib (KO-2806) follows the company’s farnesyl transferase inhibitor program, including studies in combination with cabozantinib for clear cell renal cell carcinoma.
Kura Oncology (NASDAQ: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its upcoming participation in the Bank of America Securities 2025 Healthcare Conference. The company's President and CEO, Troy Wilson, Ph.D., J.D., will engage in a fireside chat on May 13, 2025, at 6:00 p.m. ET / 3:00 p.m. PT. Investors can access a live audio webcast of the presentation through Kura's website, with a replay available afterward.
Kura Oncology (KURA) has initiated dosing in KOMET-015, a Phase 1 clinical trial evaluating ziftomenib in combination with imatinib for patients with advanced gastrointestinal stromal tumors (GIST) who failed imatinib treatment. The trial aims to assess safety, tolerability, and preliminary antitumor activity.
Preclinical studies showed the combination demonstrates robust antitumor activity in both imatinib-sensitive and resistant GIST models through a synthetic lethal mechanism. With 4,000-6,000 new GIST cases diagnosed annually in the U.S. and 60% of patients developing imatinib resistance within two years, ziftomenib could potentially delay or overcome this resistance.
The KOMET-015 Phase 1a/1b trial will evaluate safety, determine recommended Phase 2 dosing, and measure endpoints including clinical benefit, overall response rate, progression-free survival, and overall survival. This marks the first clinical trial combining a menin inhibitor with standard GIST treatments.
Kura Oncology (KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has scheduled its first quarter 2025 financial results announcement. The company will release its Q1 2025 results after U.S. market close on Thursday, May 1, 2025.
Management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss financial performance and provide a corporate update. Investors can access the live call via phone using the numbers (800) 245-3047 (domestic) or (203) 518-9765 (international) with conference ID: KURAQ1. A live webcast and replay will be available through the investor relations section of Kura's website.
Kura Oncology (KURA) and Kyowa Kirin have submitted a New Drug Application (NDA) to the FDA for ziftomenib, their oral menin inhibitor designed to treat adult patients with relapsed or refractory acute myeloid leukemia (AML) with NPM1 mutation.
The submission was completed on March 31, 2025, with FDA expected to determine application completeness within 60 days. Ziftomenib has received Breakthrough Therapy, Fast Track, and Orphan Drug Designations. The company has requested Priority Review, which could result in a six-month FDA review period if granted.
This therapeutic candidate represents a potential first FDA-approved targeted therapy for NPM1-mutant AML patients, addressing an significant unmet medical need in this devastating disease.
Kura Oncology (NASDAQ: KURA) has announced the granting of inducement awards to four new employees as approved by the Company's Compensation Committee on April 1, 2025. The awards consist of nonstatutory stock options to purchase 79,500 shares of common stock under the Company's 2023 Inducement Option Plan.
The stock options have an exercise price of $6.38 per share, matching Kura's closing sales price on April 1, 2025. The vesting schedule spans four years, with 25% of shares vesting after one year and the remaining balance vesting monthly over the subsequent 36 months, contingent on continued employment.
Kura Oncology (NASDAQ: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its upcoming participation in the Stifel 2025 Virtual Targeted Oncology Forum.
The company's President and CEO, Troy Wilson, Ph.D., J.D., will engage in a virtual fireside chat scheduled for April 8, 2025, at 10:30 a.m. ET / 7:30 a.m. PT. Investors and interested parties can access the live audio webcast through the Investors section of Kura's website, with a replay available after the event.
Kura Oncology (NASDAQ: KURA) announced that preclinical data for its next-generation farnesyl transferase inhibitor (FTI) KO-2806 has been selected for oral presentation at the 2025 AACR Annual Meeting in Chicago.
The presentation will focus on KO-2806's combination with cabozantinib, a tyrosine kinase inhibitor (TKI), in clear cell renal cell carcinoma (ccRCC). The oral presentation, titled 'Farnesyl transferase inhibitor KO-2806 enhances the antitumor activity of cabozantinib in ccRCC tumors that progress on anti-VEGFR agents,' is scheduled for April 28, 2025.
The company expects to present data from the Phase 1 FIT-001 trial evaluating KO-2806 both as monotherapy and in combination with cabozantinib for RCC treatment in the second half of 2025.